Form 4 for TXG 10x Genomics, Inc.
Accepted 2021-12-15 00:00:00 ET · period of report 2021-12-13 · accession 0001567619-21-022118 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-12-15 | 2021-12-13 | TXG | CRUTCHFIELD BRADFORD | Chief Commercial Off | S - Sale+OE | $139.36 | -17.0K | 44.0K | -28% | -$2.37M |
| D | 2021-12-15 | 2021-12-13 | TXG | CRUTCHFIELD BRADFORD | Chief Commercial Off | M - OptEx | $1.16 | +17.0K | 60.1K | +39% | +$19.7K |
| D | 2021-12-15 | 2021-12-13 | TXG | CRUTCHFIELD BRADFORD | Chief Commercial Off | M - OptEx | $0.00 | -17.0K | 426.0K | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2021-12-13 | S | D | 100 | $142.47 | 43,055 | D | — | — | |
| 2 | Common | Class A Common Stock | 2021-12-13 | S | D | 9,599 | $139.52 | 45,656 | D | — | — | (F4) This transaction was executed in multiple trades at prices ranging from $139.00 to $139.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 3 | Common | Class A Common Stock | 2021-12-13 | S | D | 3,235 | $138.60 | 55,255 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $138.00 to $138.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 4 | Common | Class A Common Stock | 2021-12-13 | S | D | 1,565 | $137.63 | 58,490 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $137.00 to $137.97. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 5 | Common | Class A Common Stock | 2021-12-13 | M | A | 17,000 | $1.16 | 60,055 | D | — | — | |
| 6 | Common | Class A Common Stock | 2021-12-13 | S | D | 800 | $141.31 | 43,155 | D | — | — | (F6) This transaction was executed in multiple trades at prices ranging from $141.02 to $141.895. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 7 | Common | Class A Common Stock | 2021-12-13 | S | D | 1,701 | $140.38 | 43,955 | D | — | — | (F5) This transaction was executed in multiple trades at prices ranging from $140.01 to $140.90. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 8 | Derivative | Stock Option (right to buy) | 2021-12-13 | M | D | 17,000 | $0.00 | 426,000 | D | $1.16 · — to 2027-02-03 | 17,000 Class A Common Stock | (F7) This option, originally for 800,000 shares, of which 374,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |